Taiwan Biomaterial Co., Ltd. (TPEX:6649)
Taiwan · Delayed Price · Currency is TWD 35.75
-0.35 (-0.97%)
Sep 18, 2026, 1:30 PM CST
Taiwan Biomaterial Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 182.32 | 220.4 | 96.57 | 72.84 | 127.31 | 41.67 | |
Revenue Growth | 15.40% | 128.22% | 32.59% | -42.79% | 205.48% | 130.56% |
Cost of Revenue | 80.27 | 85.61 | 39.27 | 25.72 | 36.94 | 9.52 |
Gross Profit | 102.05 | 134.8 | 57.31 | 47.12 | 90.37 | 32.15 |
Selling, General & Admin | 57.01 | 50.41 | 37.46 | 38.57 | 32.79 | 23.46 |
Research & Development | 26.58 | 23.55 | 31.08 | 22.78 | 32.12 | 65.41 |
Operating Expenses | 83.59 | 73.96 | 68.54 | 61.35 | 64.91 | 88.87 |
Operating Income | 18.46 | 60.83 | -11.24 | -14.23 | 25.46 | -56.72 |
Interest Expense | -0.72 | -0.74 | -0.8 | -0.87 | -0.97 | -1.03 |
Interest & Investment Income | 4.7 | 5.38 | 3.84 | 4.7 | 2.25 | 0.49 |
Currency Exchange Gain (Loss) | 5.87 | -6.89 | 3.67 | 0.27 | 6.67 | -0.63 |
Other Non Operating Income (Expenses) | 4.86 | 0.35 | 0.78 | 1.1 | 0.34 | 10.48 |
EBT Excluding Unusual Items | 33.16 | 58.93 | -3.75 | -9.03 | 33.76 | -47.4 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.04 |
Pretax Income | 33.16 | 58.93 | -2.49 | -9.03 | 33.76 | -47.44 |
Income Tax Expense | - | - | -0.76 | 1.1 | - | - |
Net Income | 33.16 | 58.93 | -1.73 | -10.13 | 33.76 | -47.44 |
Net Income to Common | 33.16 | 58.93 | -1.73 | -10.13 | 33.76 | -47.44 |
Net Income Growth | 22.48% | - | - | - | - | - |
Shares Outstanding (Basic) | 42 | 42 | 42 | 42 | 41 | 33 |
Shares Outstanding (Diluted) | 42 | 42 | 42 | 42 | 41 | 33 |
Shares Change | -0.01% | - | - | 2.73% | 23.90% | - |
EPS (Basic) | 0.79 | 1.40 | -0.04 | -0.24 | 0.83 | -1.44 |
EPS (Diluted) | 0.79 | 1.40 | -0.04 | -0.24 | 0.83 | -1.44 |
EPS Growth | 23.35% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -40.82 | 47.33 | 14.74 | -12.74 | -6.36 | -54.3 |
Free Cash Flow Per Share | -0.97 | 1.13 | 0.35 | -0.30 | -0.16 | -1.65 |
Dividend Per Share | 1.000 | 1.000 | - | - | 0.200 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 55.97% | 61.16% | 59.34% | 64.69% | 70.99% | 77.15% |
Operating Margin | 10.12% | 27.60% | -11.63% | -19.53% | 20.00% | -136.10% |
Profit Margin | 18.19% | 26.74% | -1.79% | -13.91% | 26.52% | -113.84% |
Free Cash Flow Margin | -22.39% | 21.47% | 15.26% | -17.49% | -5.00% | -130.31% |
EBITDA | 29.44 | 71.97 | 0.99 | -2.28 | 36.02 | -51.8 |
EBITDA Margin | 16.15% | 32.65% | 1.03% | -3.14% | 28.29% | -124.29% |
D&A For EBITDA | 10.98 | 11.14 | 12.23 | 11.94 | 10.55 | 4.92 |
EBIT | 18.46 | 60.83 | -11.24 | -14.23 | 25.46 | -56.72 |
EBIT Margin | 10.12% | 27.60% | -11.63% | -19.53% | 20.00% | -136.10% |